BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
812 results:

  • 1. A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and myc that promotes group 3 medulloblastoma.
    Katsushima K; Joshi K; Yuan M; Romero B; Batish M; Stapleton S; Jallo G; Kolanthai E; Seal S; Saulnier O; Taylor MD; Wechsler-Reya RJ; Eberhart CG; Perera RJ
    Cell Rep; 2024 Mar; 43(3):113938. PubMed ID: 38460130
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ICBP90, an epigenetic regulator, induces DKK3 promoter methylation, promotes glioma progression, and reduces sensitivity to cis-platinum.
    Cao Q; Wang X; Liu J; Dong Y; Wu X; Mi Y; Liu K; Zhang M; Shi Y; Fan R
    Exp Cell Res; 2024 Mar; 436(2):113976. PubMed ID: 38401687
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-myc pathway by targeting the splicing factor NONO.
    Chen Y; Xu X; Ding K; Tang T; Cai F; Zhang H; Chen Z; Qi Y; Fu Z; Zhu G; Dou Z; Xu J; Chen G; Wu Q; Ji J; Zhang J
    J Exp Clin Cancer Res; 2024 Feb; 43(1):39. PubMed ID: 38303029
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-myc-UHRF1 interactions.
    Xue Z; Zhang Y; Zhao R; Liu X; Grützmann K; Klink B; Zhang X; Wang S; Zhao W; Sun Y; Han M; Wang X; Hu Y; Liu X; Yang N; Qiu C; Li W; Huang B; Li X; Bjerkvig R; Wang J; Zhou W
    J Exp Clin Cancer Res; 2024 Jan; 43(1):25. PubMed ID: 38246990
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
    Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
    Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates.
    Gopalan A
    Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 myc-amplified Medulloblastoma.
    Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
    J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in myc-amplified medulloblastoma cells.
    Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
    J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
    Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
    JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of myc stability.
    Wang Z; Cai H; Li Z; Sun W; Zhao E; Cui H
    Clin Epigenetics; 2023 Dec; 15(1):192. PubMed ID: 38093312
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Mitotic Dysregulation at tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for mycN-Driven Neuroblastoma.
    Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
    [No Abstract]    [Full Text] [Related]  

  • 12. Anti-melanoma and antioxidant properties of the methanol extract from the leaves of
    Evariste Leonce AA; Devi P; Richard TS; Panda B; Devabattula G; Godugu C; Phelix Bruno T
    J Complement Integr Med; 2024 Mar; 21(1):88-100. PubMed ID: 37916849
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. tumor Profiles of Late Presentation Uveal Ring Melanoma With Novel Characteristics - A Case Series.
    Lim JZ; Crawford AZ; McGhee CNJ
    Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):44. PubMed ID: 37889509
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Sequential activation of E2F via Rb degradation and c-myc drives resistance to CDK4/6 inhibitors in breast cancer.
    Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
    Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. TRAIL and Celastrol Combinational treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma cells via Targeting Wnt/β-catenin Signaling Pathway.
    Qin JJ; Niu MD; Cha Z; Geng QH; Li YL; Ren CG; Molloy DP; Yu HR
    Chin J Integr Med; 2024 Apr; 30(4):322-329. PubMed ID: 37861963
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Posttreatment complications in pediatric cervical neuroblastoma: A retrospective case series at a tertiary cancer center.
    Lopez J; Subramanian T; Durell J; Levyn H; Wong R; Shah J; LaQuaglia MP; Gerstle JT
    J Surg Oncol; 2024 Feb; 129(2):219-223. PubMed ID: 37850570
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting myc-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation.
    Jiang P; Zhang T; Wu B; Li X; Fu M; Xu B
    Med Oncol; 2023 Oct; 40(11):332. PubMed ID: 37843625
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comparative Analysis of the Embryonal Brain tumors Based on Their Molecular Features.
    Shcherbina V; Kovalevska L; Pedachenko E; Malysheva T; Kashuba E
    Discov Med; 2023 Oct; 35(178):733-749. PubMed ID: 37811612
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identifying predictors of glioma evolution from longitudinal sequencing.
    Mu Q; Chai R; Pang B; Yang Y; Liu H; Zhao Z; Bao Z; Song D; Zhu Z; Yan M; Jiang B; Mo Z; Tang J; Sa JK; Cho HJ; Chang Y; Chan KHY; Loi DSC; Tam SST; Chan AKY; Wu AR; Liu Z; Poon WS; Ng HK; Chan DTM; Iavarone A; Nam DH; Jiang T; Wang J
    Sci Transl Med; 2023 Oct; 15(716):eadh4181. PubMed ID: 37792958
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Class I HDAC inhibition reduces DNA damage repair capacity of myc-amplified medulloblastoma cells.
    Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
    J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 41.